“We aim to understand the heterogeneity of psychiatric disorders, the variability in medication treatment and what the genetic contributions are in both. As researchers and healthcare providers, we have the responsibility to minimize harm to patients.”
— Dr. Daniel Mueller
Dr. Daniel Mueller, MD PhD
Principal Investigator, Clinician-Scientist
Department of Pharmacology and Toxicology | University of Toronto
Department of Psychiatry | University of Toronto
Institute of Medical Science | University of Toronto
Molecular Brain Science | CAMH
Dr. Mueller is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).
Dr. Mueller earned his MD at the University of Bonn (Germany) and completed his residency training at the Charité University Clinic in Berlin. He has then been appointed as a Professor at the University of Toronto (Departments of Psychiatry and Pharmacology & Toxicology) and a Clinician Scientist at the Centre for Addiction and Mental Health (CAMH) in Toronto since 2008.
Throughout his career, Dr. Mueller’s research goals have been to investigate genetic causes of response and side effects to psychiatric medications on which he published more than 200 articles. This line of research aims to significantly improve the treatment of psychiatric conditions and to lessen the burden of medication side effects and avoid adverse drug-drug interactions.
He has received international recognition for his contributions and was awarded the Michael Smith Prize for Research in Schizophrenia by the Canadian Institutes of Health Research (CIHR, 2010), the Klerman Prize for Exceptional Research in Clinical Brain and Behaviour Science (Honorable Mention) by the Brain and Behaviour Research Foundation (NARSAD, 2013), the Innovation in Psychopharmacology Award by the Canadian College of Neuropsychopharmacology in 2016 and the Personalized Medicine Research Award by the German Psychiatric Association (DGPPN) in 2019.
Follow Dr. Mueller on Twitter (see also #PGxRC) and Google Scholar!
For publications, see our research.